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Background: Recent studies have shown that glucosamine inhibits the proliferation of various human cancer cell
lines and downregulates the activity of COX-2, HIF-1α, p70S6K, and transglutaminase 2. Because the IGF-1R/Akt
pathway is a common upstream regulator of p70S6K, HIF-1α, and COX-2, we hypothesized that glucosamine inhibits
cancer cell proliferation through this pathway.
Methods: We used various in vitro assays including flow cytometry assays, small interfering RNA (siRNA)
transfection, western blot analysis, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays, reverse
transcription-polymerase chain reaction, and in vivo xenograft mouse model to confirm anticancer activities of
glucosamine and to investigate the molecular mechanism.
Results: We found that glucosamine inhibited the growth of human non-small cell lung cancer (NSCLC) cells and
negatively regulated the expression of IGF-1R and phosphorylation of Akt. Glucosamine decreased the stability of
IGF-1R and induced its proteasomal degradation by increasing the levels of abnormal glycosylation on IGF-1R.
Moreover, picropodophyllin, a selective inhibitor of IGF-1R, and the IGF-1R blocking antibody IMC-A12 induced
significant cell growth inhibition in glucosamine-sensitive, but not glucosamine-resistant cell lines. Using in vivo
xenograft model, we confirmed that glucosamine prohibits primary tumor growth through reducing IGF-1R
signalling and increasing ER-stress.
Conclusions: Taken together, our results suggest that targeting the IGF-1R/Akt pathway with glucosamine may be
an effective therapeutic strategy for treating some type of cancer.
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Since the effect of glucosamine as an inhibitor of tumor
growth was first reported by Quastel and Cantero, [1]
many in vitro studies have shown that it interferes with
the glycoslyation of glycoproteins, [2,3] decreases the rate
of glycolysis and fructolysis, [4,5] and changes the compo-
nent ratio of nucleotides in various carcinoma cell lines
[6,7]. Results of a recent study indicated that glucosamine
induces G1 cell-cycle arrest in mesangial cells and human
cancer cells through a mechanism involving decreased
expression of cyclin D1 and increased expression of* Correspondence: eyeball@hanmail.net
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stated.p21Waf1/Cip1, which are positive and negative regulators of
cell cycle progression, respectively [8,9].
The PI3K/Akt pathway is often overactivated in various
types of cancer cells. PI3K/Akt can transmit signals from
RTKs and G-protein-coupled receptors that are activated
by growth factors or cytokines; therefore, the PI3K/Akt
signal transduction pathway regulates multiple cellular
functions, including transcription, translation, and cell
proliferation, cell cycle progression, and survival [10-12].
Although the RTK-mediated signal transduction pathways
overlap, PI3K-mediated activation of Akt specifically con-
tributes to the anti-apoptotic activity of IGF-1R.
Recent studies have demonstrated that target proteins
of glucosamine may exist in cancer cells [13-16]. Glucosa-
mine inhibits the growth of cancer cells by downregu-
lating the phosphorylation of p70S6K, a regulator oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Primer sequences used for RT-PCR
Gene Primer sequence (5′ - 3′)
IGF-1R F 5′-ACG CCA ATA AGT TCG TCC AC-3′
R 5′-TCC ATC CTT GAG GGA CTC AG-3′
COX-2 F 5′-ATC TTT GGG GAG ACC ATG GTA GA-3′
R 5′-ACT GAA TTG AGG CAG TGT TGA TG-3′
XBP1 F 5′-TTA CGA GAG AAA ACT CAT GGC C-3′
R 5′-GGG TCC AAG TTG TCC AGA ATG C-3′
GRP78 F 5′-GGT ACA TTT GAT CTG ACT G-3′
R 5′-CAC TTC ACT AGA GTT TGC TG-3′
CHOP F 5′-CTT CAC TAC TCT TGA CCC TGC AT-3′
R 5′-ATG TGC ACT GGA GAT TGC TT-3′
ATF4 F 5′-GTT CTC CAG CGA CAA GGC TA-3′
R 5′-ATC CTC CTT GCT GTT GTT GG-3′
GAPDH F 5′-GGT GAA GGT CGG TGT GAA CGG ATT T-3′
R 5′-ATT GCC AAA GTT GTC ATG GAT GAC C-3′
β-ACTIN F 5′-GTG GGG CGC CCC AGG CAC CA-3′
R 5′-CTC CTT AAT GTC ACG CAC GAT TTC-3′
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http://www.biomedcentral.com/1471-2407/14/31protein translation [15]. In addition, glucosamine in-
hibits HIF-1α by inhibiting protein translation through
the reduction of phosphorylated p70S6K levels [16].
Jang et al. reported that glucosamine hydrochloride in-
hibits N-glycosylation of COX-2 and enhances COX-2
protein turnover [13]. Finally, glucosamine induces
NF-κB inactivation by inhibiting transglutaminase 2
(TGase 2) activity [14]. Together, these studies suggest
that glucosamine has potential as an anticancer drug,
although its mechanism of action remains poorly under-
stood [17]. Thus, we tested whether the IGF-1R/PI3K/
Akt pathway, upstream of p70S6K and COX-2, is target
of glucosamine. We also investigated the molecular
mechanisms underlying the anticancer activity of glu-
cosamine in NSCLC cells.
Methods
Cell lines and materials
Human NSCLC cell lines A549, H226B, H1299, and
H460 were purchased from the American Type Culture
Collection (Manassas, VA, USA).
The HA-Akt1 (T308D/S473D) expression vector was
kindly provided by Dr. Gordon Mills (The University of
Texas MD Anderson Cancer Center). The H226B-Babe
cells were produced by infecting H226B NSCLC cells with
a pBabe retroviral control vector. The H226B-Akt1-DD
cells that possess a constitutively active form of Akt were
produced by infecting H226B with a pBabe-HA-Akt1-DD
construct harboring mutations that change Ser473 and
Thr308 to aspartic acids. The H226B-Akt2-DD and The
H226B-Akt3-DD cells were kindly provided by Dr. Ho-
Young Lee (College of Pharmacy, Seoul National Univer-
sity, Seoul, Republic of Korea).
D-(+)-Glucosamine hydrochloride, MG132, and tunica-
mycin (TN) were purchased from Sigma-Aldrich (St Louis,
MO, USA). Antibodies against pIGF-1R, pAkt, pERK1/2,
Akt, PTEN, PARP, PDI, IRE1α, ATF4, GRP78, CHOP, and
a/β-tubulin were purchased from Cell Signaling Tech-
nology (Beverly, MA, USA). Antibodies against IGF-1R,
COX-2, CDK2, CDK4, and β- ACTIN were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA), and the antibody against TGase 2 was obtained
from Thermo Fisher Scientific, Inc. (Fremont, CA, USA).
Xenograft mouse tumor model
All animal experimental procedures were approved by
Institutional Animal Care and Use Committee (IACUC)
of National Cancer Center in Republic of Korea. To con-
firm antitumor effect of glucosamine in animal, we used
xenograft tumor model. A549 cells (5 x 106 cells) were
subcutaneously injected into flank region of BALB/c
nude mice. After cancer cell injection, glucosamine
(500 mg/kg body weight/day) was administered intrape-
nitorially to immuoncompromised mice. Tumor volumewas measured using caliper and calculated according to
the formula (L x W2)/2. All of the mice were sacrificed
on Day 71, and tumor tissues were isolated from them.
The results were represented as the mean of tumor
volumes (n = 10) with SEM.
siRNA transfection
For RNA interference, A549, H1299, and H460 cells trans-
fected with 40 nM siRNA. Double-stranded siRNAs de-
signed to target IGF-1R (5′-CUG ACA UGG GCC UUU
AAG A-3′), and a scrambled non-targeting siRNA were
synthesized by Bionner (Seoul, South Korea). Cells were
transfected with siRNAs using Lipofectamine reagent
(Invitrogen, CA, USA) according to the manufacturer’s
protocol.
Semiquantitative RT-PCR
First strand cDNA was synthesized from 2 μg of extracted
RNA using M-MLV reverse transcriptase (Invitrogen).
RT-PCR was carried out with gene-specific primers for
IGF-1R, COX-2, XBP1, GRP78, CHOP, ATF4, GAPDH,
and β-ACTIN (Table 1). Primers amplifying a region of
β-ACTIN or GAPDH were used as an internal control.
Western blot analysis
Preparation of whole-cell lysates from cancer cells, elec-
trophoresis, and membrane transfer were performed as
previously described [18]. The membranes were then
incubated overnight at 4°C with primary antibodies in
TBS-T containing 5% bovine serum albumin. Membranes
were washed with TBS-T and then incubated with an
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antibody in 5% skim milk for 1 hour at room temperature.
Cell proliferation analysis
To determine the effects of glucosamine on the proli-
feration of various cancer cell lines, cells were seeded in
96-well plates (3,000 cells/well). On the following day, the
medium was replaced with medium containing glucosa-
mine, picropodophyllin, and A12 at the desired concentra-
tions. After incubation for an additional 2 days, MTT
assay was performed according to standard procedures.
The bars represent SD of results.
Cell cycle analysis
For the cell cycle analysis, three human NSCLC cell lines
were treated with the indicated concentration of glucosa-
mine. Floating and attached cells were fixed in 70% etha-
nol for 1 hour at 4°C. After centrifugation, the cell pellet
was washed twice with phosphate-buffered saline (PBS)
and stained with propidium iodide (PI) containing RNase
A (40 μg/ml) for 30 minutes at 4°C in the dark. The total
cellular DNA content of each cancer cell line was quanti-
fied by flow cytometry.
Apoptosis analysis
To analyze the number of apoptotic cells after 2 days of
glucosamine treatment, A549, H1299, and H460 cells were
harvested and washed twice with PBS on ice. The cells
were resuspended in 1 X binding buffer containing 5 μl
fluorescein isothiocyanate (FITC)-conjugated Annexin V
and 5 μl PI. Apoptotic events were detected by flow
cytometry at 488 nm and 633 nm using the FITC Annexin
V apoptosis detection kit I (BD Pharmingen, San Jose,
CA). All procedures were carried out according to the
manufacturer’s instructions.
Immunohistochemistry
Primary tumors from PBS or glucosamine treated animals
were embedded in paraffin depending on the application.
The 5 μm tumor tissue sections were prepared for immu-
nohistochemistry. Paraffin sections were incubated over-
night at 4°C with primary antibody against anti-phospho-
Akt (Cell Signaling Technology; 1 : 100 dilution) and then
processed for avidin – biotin immunohistochemistry ac-
cording to the manufacturer’s instructions (Vector Labora-
tories, Burlingame, CA). These sections counterstained
with hematoxylin and eosin-Y (H&E). Immunohistochemi-
cal analysis were performed as previously described [18].
Results
Glucosamine induces cell cycle arrest and apoptosis in
NSCLC cells
Previous studies have reported that glucosamine inhibits
cell growth [15,16] and cell-cycle progression [8,9,19]and induces apoptosis [20] in various cell lines. We
therefore investigated whether the anti-cancer effect of
glucosamine was associated with cell growth, cell-cycle
arrest and apoptosis in NSCLC cell lines. Glucosamine
reduced the proliferation of all four NSCLC cell lines,
but the extent of the inhibition differed among NSCLC
cell lines (Figure 1A). Flow cytometric analysis indicated
that glucosamine induced cell-cycle arrest at the G0/G1
phase in a dose-dependent manner (Figure 1B) and that
glucosamine induced apoptosis in A549, H226B, H1299,
and H460 NSCLC cell lines (Figure 1C and Additional
file 1: Figure S1). Consistent with the results of the cell
proliferation assay, in the cell cycle and apoptosis ana-
lyses, the A549 and H226B cells had a more significant
response to glucosamine than the others.
In addition, expression of cleaved poly-(ADP-ribose)
polymerase (PARP), a marker for apoptosis, was high in
A549 and H226B cells and low in H460 cells (Figure 1D).
Treatment with 5 mM glucosamine reduced the expres-
sion of both CDK4 and CDK2 in A549 and H226B cells
and that of CDK4 only in H1299 cells. In contrast, the
levels of CDK4 and CDK2 were not obviously changed
in H460 cells (Figure 1D). These findings suggest that
the glucosamine-mediated growth inhibition of NSCLC
cells is associated with the induction of cell-cycle arrest
and apoptosis.The basal expression levels of TGase 2 and COX-2 proteins
in NSCLC cells are not correlated with glucosamine
sensitivity
We investigated the expression levels of TGase 2 and
COX-2 proteins that were previously identified as major
targets of glucosamine. Expression of TGase 2 was
markedly higher in A549 and H1299 cells than in H460
and H226B cells. We also found that A549 and H460
cell lines showed a high basal level of COX-2 expression,
whereas COX-2 expression was not detected in H1299
cells (Additional file 2: Figure S2). Therefore, the basal
TGase 2 and COX-2 levels in the NSCLC cell lines were
not correlated with glucosamine sensitivity.Glucosamine suppresses activation of Akt by reducing
IGF-1R expression in cell lines that have an
IGF-1R-dependent Akt activation pathway
Because we observed that glucosamine downregulated
CDK4 expression in NSCLC cells (Figure 1D) and a pre-
vious report showed that the PI3K/Akt pathway affects
CDK4 expression [21], we tested the effect of glucosamine
on the IGF-1R/Akt signaling pathway. Glucosamine re-
duced the IGF-1R and pAkt levels in A549 and H460 cell
lines in a dose-dependent manner (Figure 2A). Moreover,
activation of both pIGF-1R and pAkt by IGF-1 was down-
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Figure 1 (See legend on next page.)
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Figure 1 Effect of glucosamine on cell growth, cell cycle arrest, and apoptosis in NSCLC cells. (A) MTT growth assay of A549, H1299, and
H460 cells. *P < 0.05 compared with glucosamine 0 mM. (B) NSCLC cells were treated with glucosamine for 2 days and then stained with PI for
cell-cycle analysis. (C) Apoptosis/necrosis was determined by Annexin V-FITC and PI staining. (D) The protein levels of CDK2, CDK4, PARP, and
cleaved PARP.
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Akt signal transduction.
All cell lines showed a dose-dependent decrease in
IGF-1R expression, but there was a significant reduction
in pAkt expression in the A549 and H226B cell lines
(Figure 2C). To confirm that glucosamine inhibited the
IGF-1R/Akt signaling pathway, we also carried out small
interfering RNA (siRNA) transfection studies. IGF-1R
expression was completely abolished following treatment
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Figure 2 Glucosamine down-regulates the IGF-1R kinase-dependent A
glucosamine in A549 cells. (B) A549 cells were pretreated with glucosamin
of glucosamine on different NSCLC cell lines. (D) A549 cells transfected wit
1-day treatment with 1 mM glucosamine. (E) Cell proliferation assay in NSC
of glucosamine for 2 days. * P < 0.05 compared with siSCR-transfected cellsSimilarly, pAkt expression was completely abolished in
cells cotreated with glucosamine and siIGF-1R (Figure 2D).
We next performed MTT assay on NSCLC cells to
determine whether a combination of siIGF-1R and glu-
cosamine inhibits cell proliferation more efficiently than
either agent alone. As expected, IGF-1R knockdown
enhanced the glucosamine-induced inhibition of cell
growth in the A549 cell line but not the H460 cell
line in which siIGF-1R did not affect the pAkt level
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.
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http://www.biomedcentral.com/1471-2407/14/31inhibits the proliferation of NSCLC cells by reducing
the expression of IGF-1R, and the extent of the glucosa-
mine-induced reduction in the pAkt level is associated
with the anticancer effect of glucosamine.
Glucosamine and other IGF-1R–targeting agents have
similar effects in glucosamine-sensitive and -resistant cell
lines
We hypothesized that if glucosamine acts as an IGF-1R-
specific inhibitor, siIGF-1R and other agents that inhibit
IGF-1R will exhibit anticancer effects similar to those
induced by glucosamine in the A549 and H460 cell lines.
Thus, we investigated whether molecules inhibiting IGF-
1R also reduce the pAkt level and inhibit cell proli-
feration in these cell lines. First, siIGF-1R dramatically






































Figure 3 The inhibitory effect of glucosamine and IGF-1R targeting ag
IGF-1R on the pAkt level and cell growth. (B and C) Western blotting (left)
A12 (C) at the concentrations indicated. *P < 0.05 denotes significant differonly partially reduced the pAkt level in the A549 cell
line. In addition, an antisense oligonucleotide targeting
IGF-1R only inhibited the growth of the A549 cells
(Figure 3A). In addition to siIGF-1R, picropodophyllin
(PPP), an IGF-1R-specific small-molecule inhibitor, re-
duced the levels of pIGF-1R and pAkt and inhibited the
growth of A549 cells more efficiently than that of H460
cells (Figure 3B).
One of IGF-1R blocking antibodies, A12, binds directly
to IGF-1R and promotes its internalization and degra-
dation [22]. A12 significantly reduced the level of IGF-1R
in both A549 and H460 cells (Figure 3C). The pAkt levels
were dramatically reduced in the A549 cell line but only
slightly reduced in the H460 cell line. In concordance with
these results, A12 reduced the proliferation of A549 cells
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http://www.biomedcentral.com/1471-2407/14/31These results suggest that IGF-1R is one of the major pro-
tein targets of glucosamine in various types of cancer cells
that have an IGF-1R-dependent Akt signal transduction
pathway.
Constitutive activation of Akt1 alleviates the growth-
inhibitory effect of glucosamine in H226B human NSCLC
cells
To evaluate whether constitutive activation of Akt iso-
forms alters the anti-proliferative effect of glucosamine,
H226B-Babe and H226B-Akt1-DD cells were treated
with various concentrations of glucosamine for 3 days.
Glucosamine effectively suppressed the proliferation of





































































Figure 4 The role of Akt1 in the glucosamine-induced regulation of c
incubated with 0.5 ~ 10 mM glucosamine for 3 days and the MTT assay wa
serum conditions. *P < 0.05 compared with H226B-Babe cells. (C) Adherentof H226B-Akt1-DD cells (Figure 4A). Under normal
culture conditions (10% FBS), 10 mM glucosamine re-
duced the viability of H226B-Babe and H226B-Akt1-DD
cells to 22.1% ± 3.6% and 32.9% ± 3.7% viable cells,
respectively. Interestingly, the changes in cell viability
were more pronounced in the cells treated under normal
culture conditions than in those grown in media contain-
ing 1% FBS (Figure 4B). PARP cleavage also was not
detected in H226B-Akt1-DD cells exposed to glucosamine
(Figure 4C), and we detected only minimal induction of
PARP cleavage in H226B-Babe cells treated with 10 and
20 mM glucosamine. These results suggest that constitu-










































ell proliferation in H226B cells. (A) The indicated cells were
s performed. (B) An MTT assay was carried out under low and high
and floating cells were analyzed using western blotting.
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translational modification and proteasome-dependent
manner
We next investigated whether the suppression of IGF-1R/
Akt signal transduction by glucosamine occurred at the
transcriptional and/or translational level. First, we ob-
served that glucosamine treatment did not change the
levels of either IGF-1R or COX-2 mRNA (Figure 5A).
These findings led us to examine whether the observed
decrease in the IGF-1R protein level following exposure to
glucosamine was associated with the stability of the IGF-
1R protein. The proteasome inhibitor MG132 restored the
IGF-1R level in cells treated with 1 mM glucosamine but-actin
IGF-1R
COX-2
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Figure 5 Glucosamine inhibits IGF-1R at the post-translational level. (
in A549 cells. (B) A549 cells were treated with the indicated doses of gluco
were pretreated with the indicated concentrations of glucosamine for 16 h
treated with the indicated concentrations of glucosamine or tunicamycin f
0.5 μg/ml tunicamycin for 12 hours in the absence or presence of 25 μM M
stress- and unfolded protein response-related genes was performed usingnot in cells treated with 5 mM glucosamine. In contrast,
pAkt expression was fully rescued in cells treated with
1 mM glucosamine (Figure 5B). A previous study reported
that glucosamine accelerated the proteasome-dependent
degradation of only the higher molecular weight species of
COX-2; [13] however, our results showed that both higher
and lower molecular weight species of COX-2 were re-
stored when cells were treated with either 1 mM or 5 mM
glucosamine. In addition to COX-2, the molecular mass of
prototype IGF-1R (pro-IGF-1R) was also reduced by glu-
cosamine in a dose-dependent manner (Figure 5B). We
next explored whether the glucosamine-induced decrease
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A) Semiquantitative RT-PCR analysis of IGF-1R and COX-2 mRNA levels
samine and the proteasome inhibitor MG132 for 1 day. (C) A549 cells
ours and then with cycloheximide for 2 hours. (D) A549 cells were
or 6 hours. (E) A549 cells were treated with 1 mM glucosamine or
G132. (F) Western blot analysis of the expression of various ER
cell lysates from harvested A549 cells.
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the de novo biosynthesis of pro-IGF-1R in A549 cells, and
glucosamine did not affect the IGF-1R, pAkt, and COX-2
levels (Figure 5C). These findings collectively suggest that
glucosamine may induce the hypoglycosylation of pro-
IGF-1R and COX-2 and facilitate their degradation at the
post-translational level.
Besides, more recent studies have shown that glucosa-
mine inhibits N-glycosylation of certain proteins including
COX-2, glucose transporter1, and a lipoprotein apo-B-100
[13,23,24]. Therefore, we next tested whether glucosamine
induces abnormal N-glycosylation of pro-IGF-1R protein.
As shown in Figure 5D, glucosamine treatment obviously
prevented pro-IGF-1R glycosylation in concentration
dependent manner, resulting in low molecular mass of
that. Tunicamycin (TN), the protein N-glycosylation in-
hibitor, was used as a positive control to confirm the effect
of glucosamine on pro-IGF-1R N-glycosylation. We next
challenged whether glucosamine-induced abnormal glyco-
sylation of pro-IGF-1R protein is recovered by MG132. As
depicted in Figure 5E, reduction of pro-IGF-1R molecular
mass by glucosamine was remarkably restored by treating
A549 cells with MG132. In addition, previous studies have
elucidated that glucosamine caused endoplasmic reti-
culum (ER) stress and activated a series of signaling path-
way termed the unfolded protein response (UPR) [3,25].
We also confirmed that glucosamine induces ER stress
and activates the UPR through changing of various
marker genes including spliced XBP1, PDI, IRE1α ATF4,
GRP78, and CHOP (Figure 5F and Additional file 3:
Figure S3). Overall, these data demonstrate that glucosa-
mine negatively affects IGF-1R and COX-2 protein sta-
bility through a proteasome-dependent pathway, and the
production of hypoglycosylated pro-IGF-1R by glucosa-
mine is associated with this pathway.
Glucosamine suppress primary tumor growth in vivo
To determine whether glucosamine inhibits primary tu-
mor initiation and growth in vivo, glucosamine-sensitive
A549 cells were injected subcutaneously into immuno-
compromised mice. After injection, tumor bearing mice
were treated with PBS or glucosamine intraperitoneally.
As shown in Figure 6A, glucosamine significantly de-
creased subcutaneous tumor growth. Although glu-
cosamine did not totally suppress the tumor growth,
outgrowth of tumor mass was effectively reduced by glu-
cosamine treatment (Figure 6B). pIGF-1R level signifi-
cantly was decreased in glucosamine treated tumor tissues
compared with PBS treated samples (Figure 6C). We
found that glucosamine treated primary tumor showed
moderately reduced pAkt level (Figure 6E), although the
difference in western blot analysis was not significant
(Figure 6C). In addition, RT-PCR data showed that glu-
cosamine induced ER-stress in tumor tissue (Figure 6D).These findings suggest that glucosamine can inhibit pri-
mary tumor formation in vivo as well as cell proliferation
in vitro through restraining the IGF-1R/Akt signaling by
glucosamine-induced ER-stress.
Discussion
In this study, we showed that glucosamine effectively in-
hibits IGF-1R-mediated Akt signal transduction in va-
rious human carcinoma cell lines by both suppressing
IGF-1-induced IGF-1R activation and reducing IGF-1R
protein stability.
Some investigators have reported that glucosamine in-
duces cell-cycle arrest at the G0/G1 phase in human
cancer cells [26,27]. These studies have shown that this
phenomenon is mediated by decreased cyclin D1 ex-
pression and increased p21waf1/cip1 expression. Here, we
showed that in three NSCLC cell lines, glucosamine
could also downregulate CDK4 and CDK2 expression
and that the extent of the glucosamine-mediated inhib-
ition of these proteins reflected the proportion of cells
arrested in the G0/G1 phase (Figure 1B and D). In
addition, Lee et al. reported that expression of CDK4 is
associated with PI3K/Akt and that the PI3K inhibitor
LY294002 decreases the CDK4 level in corneal endothe-
lial cells [21]. In our study, the pAkt level was more ef-
fectively reduced by glucosamine in A549 and H226B
cells, which exhibited more significant decreases in CDK
levels than either the H1299 or H460 cells (Figure 2C
and Figure 1D). Similarly, because pAkt is a positive
regulator of cell survival and anti-apoptotic events, the
glucosamine-induced increase in apoptosis and cleaved
PARP were more evident in A549 cells than in the other
cell lines (Figure 1C and D).
Interestingly, we found no significant differences in the
total pAkt level in primary tumors derived from glucosa-
mine treated animal although pIGF-1R level was signifi-
cantly decreased (Figure 6C). However, we also confirmed
the decrease of Akt activation in glucosamine treated
tissue using histology analysis (Figure 6E). These conflict-
ing findings were probably resulted from drug delivery
system. Until 40 days after injection, glucosamine defi-
nitely reduced the primary tumor growth. However, after
that, the effect of glucosamine was decreased (Figure 6A)
and COX-2 level rather increased in the tumor mass
(Figure 6C). According to tumor mass getting bigger and
bigger, it is difficult that glucosamine could not penetrate
into primary tumor. Thus, insufficient dose of glucosa-
mine may partially decrease pAkt level. In addition, the
complex tumor microenvironment and the presence of
multiple redundant survival pathways at the primary
tumor site may reduce the effect of glucosamine and com-
pensate the pAkt activation.
Exogenous glucosamine can be transported across the
hydrophobic cell membrane through facilitative glucose
ATubulin
























Figure 6 Glucosamine represses primary tumor growth in vivo. (A) Xenograft experiment for anticancer activity of glucosamine was performed.
A549 cells were injected subcutaneously into the BALB/c nude mice. (B) Distribution histogram represents the individual signals of mice in each group at
day 71. (C - D) Tumor tissues extracted from each mice were used for western blotting (C) and RT-PCR (D). (E) Immunohistochemistry of phosphorylated
Akt (pAkt). Bars, 50 μm.
Song et al. BMC Cancer 2014, 14:31 Page 10 of 12
http://www.biomedcentral.com/1471-2407/14/31transporters (GLUTs) [8,28]. Once inside the cell, glu-
cosamine is converted to UDP-N-acetylglucosamine
(UDP-GlcNAc), the substrate for O-GlcNAc modifica-
tion, through the hexosamine pathway [8]. UDP-GlcNAc
covalently modifies cytosolic and nuclear proteins, in-
fluencing the stability, localization, enzymatic activity,
protein-protein interactions, and phosphorylation status
of target proteins [29]. Thus, intact O-GlcNAc modifica-
tion is very important for proper cell cycle progression,
and increasing O-GlcNAc modification of cell cycle
regulators using the O-GlcNAcase inhibitor PUGNAc
causes growth inhibition that is similar to G2/M arrest
[30]. Alteration of glycosylation on the surface of target
proteins following glucosamine treatment could be re-
sponsible for the decreased CDK2 and CDK4 expression
and increased cell cycle arrest. O-GlcNAc modification
can also affect the protein turnover rate, and modified
proteins are subject to proteasome degradation [31]. We
demonstrated that glucosamine influenced the IGF-1Rprotein stability and facilitated its proteasomal degradation
(Figure 5B and C); therefore, the reduction in the IGF-
1R half-life following glucosamine treatment may result
from the alteration of glycoconjugate structures through
O-linked glycosylation. Recent studies have shown that
glucosamine inhibits COX-2N-glycosylation and increases
the COX-2 turnover rate [13]. In this study, similar effects
were also observed for the IGF-1R prototype, which
showed a reduced molecular mass (Figure 5).
Although our results suggest that glucosamine effect-
ively inhibits cell proliferation and tumor growth in A549,
some of NSCLCs such as H460 relatively show glucosa-
mine-resistant phenotype. Because the IGF-1R/Akt signa-
ling axis includes many signal regulators, such as PI3K,
PTEN, and p53, that can influence the pAkt level, [32-35]
reduction of pAkt by glucosamine could affect each cell
line differently. Therefore, we will investigate whether mu-
tation status of these genes affect glucosamine sensitivity
in various types of cancer cell including NSCLCs.
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In summary, our results indicate that glucosamine is an
effective inhibitor of the IGF-1R/Akt pathway. The fin-
dings of the present study provide evidence supporting
the value of glucosamine as an effective and non-toxic
IGF-1R blocking agent for cancer therapeutics.Additional files
Additional file 1: Figure S1. Differential effect of glucosamine-induced
apoptosis in A549 and H1299 cells. A549 and H1299 cells were treated
with 1mM glucosamine for 48 hrs. Cells were stained with Annexin
V-FITC and PI and then analyzed by flow cytometry. Results shown are
representative of three independent experiments.
Additional file 2: Figure S2. Relationship between glucosamine-
induced growth inhibition and TGase 2 expression in NSCLC cells. NSCLC
cells were grown in RPMI medium 1640 containing 10% FBS for 2 days.
Western blot analysis of the expression of TGase 2 and COX-2 was
performed using cell lysates from harvested cells.
Additional file 3: Figure S3. Glucosamine induce ER stress- and unfolded
protein response. A549 cells were treated with glucosamine and tunicamycin
for 6 hours. RT-PCR analysis was conducted with indicated gene specific
primers.
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